serum protein
Recently Published Documents


TOTAL DOCUMENTS

3622
(FIVE YEARS 341)

H-INDEX

79
(FIVE YEARS 7)

2022 ◽  
Vol 21 (1) ◽  
pp. 1-13
Author(s):  
A.SH. SULTAN

 Electrophoretic patterns of serum protein in 12 Arabian race horses acutely infected with Babesia equi revealed a significant decrease in albumin (P<0.01) and beta globulins (P<0.05) where, alpha globulins fractions significantly (P<0.01) increased. No significant (P>0.05) changes were recorded in gamma globulins fractions and total serum protein.


Author(s):  
Ebtesam Mohamed Fahmy ◽  
Mona Salah Eldin Hamdy ◽  
Reem Medhat Mahmoud ◽  
Haidy Elshebawy

Abstract Background An association between migraine and stroke has been suggested for a long period, although conclusive evidence has not been reported. Several theories about hypercoagulability have been proposed for the association of ischemic stroke and migraine especially migraine with aura. This study aimed to assess blood coagulability in patients with migraine. Results Mean serum levels of protein S and anti-thrombin III were significantly lower in migraine patients compared to control subjects. Migraine patients showed abnormal MRI findings in the form of white matter hyper-intense lesions and ischemic foci compared to healthy controls. A significant negative correlation was detected between serum protein C level and intensity of migraine headache. Also, a significant correlation was found between deficient serum protein S and abnormal findings in brain MRI. Serum protein C deficiency is an independent predictor for migraine intensity grade. Conclusions There is an association between migraine and hypercoagulability, which may indicate increased risk of cerebral ischemic events in migraine patients and suggest adding prophylactic therapy to the management strategies of such patients.


Steroids ◽  
2022 ◽  
pp. 108953
Author(s):  
Runia Roy ◽  
Steven J. Soldin ◽  
Brian Stolze ◽  
Marissa Barbieri ◽  
Shefa M. Tawalbeh ◽  
...  

Author(s):  
Surbhi Garg ◽  
Vijay Kumar Singh ◽  
Subash Chandra Sonkar ◽  
Harshit Kelkar ◽  
Shlesh Singh ◽  
...  
Keyword(s):  

Author(s):  
Rachel D Wheeler ◽  
Micsha V Costa ◽  
Asante Crichlow ◽  
Fenella Willis ◽  
Yasmin Reyal ◽  
...  

Multiple myeloma is a haematological cancer caused by malignant plasma cells in the bone marrow that can result in organ dysfunction and death. Recent novel treatments have contributed to improved survival rates, including monoclonal antibody therapies that target the CD38 protein on the surface of plasma cells. Anti-CD38 therapies are IgG kappa monoclonal antibodies that are given in doses high enough for the drug to be visible on serum protein electrophoresis as a small paraprotein. We present a case where isatuximab, the most recent anti-CD38 monoclonal antibody to be approved for treatment of myeloma, obscured the patient’s paraprotein on gel immunofixation, so that complete remission could not be demonstrated. This was resolved using the isatuximab Hydrashift assay. The interference on gel immunofixation was unexpected because isatuximab migrated in a position distinct from the patient’s paraprotein on capillary zone electrophoresis. We demonstrate the surprising finding that isatuximab migrates in a different position on gel electrophoresis compared to capillary zone electrophoresis. It is vital that laboratories are aware of the possible interference on electrophoresis from anti-CD38 monoclonal antibody therapies, and are able to recognise these drugs on protein electrophoresis. The difference in isatuximab’s electrophoretic mobility on capillary and gel protein electrophoresis makes this particularly challenging. Laboratories should have a strategy for alternative analyses in the event that the drugs interfere with assessment of the patient’s paraprotein.


Author(s):  
Liang-Jen Wang ◽  
Yu-Chi Huang ◽  
Pao-Yen Lin ◽  
Yu Lee ◽  
Chi-Fa Hung ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document